Overcoming Deadly Diseases

Phase 3 ACTION Study of ONC201 (dordaviprone) Now Enrolling

Improving and Extending Lives

Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.  Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.

For Healthcare professionals only

Chimerix is excited to announce that we will be on site at the upcoming EANO 2024 and SNO 2024 Annual Conferences. We warmly welcome you to visit our booth and meet our team. We also plan to attend these additional scientific conferences this year: ISPNO 2024, BNOS 2024, CNS Annual Meeting, ASNO 2024 and ASTRO 2024.

If you are interested in meeting with the Chimerix team, please feel free to reach out to us at [email protected] to coordinate an in-person meeting.

We look forward to connecting with you and answering any questions you may have about our programs.


view all